This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Clozapine: Diabetes Mellitus, Weight Gain, and Lipid Abnormalities

David C. Henderson, MD

Published: January 9, 2001

Article Abstract

Clozapine remains the most effective agent for treatment-resistant patients with schizophrenia.Recently, treatment with clozapine has been linked to a number of metabolic disturbances, includingweight gain, diabetes mellitus, and serum lipid abnormalities. Despite the potential risks of medicalmorbidities, clozapine continues to have a major role in the care of treatment-resistant patients withschizophrenia. This article discusses the diagnosis and significance of the above metabolic abnormalitiesand potential mechanisms for these abnormalities as well as recommendations for monitoring andtreatment.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: